NDLI: Profile and potential of ixabepilone in the treatment of pancreatic cancer

Content Provider	PubMed Central
Author	Smaglo, Brandon G. Pishvaian, Michael J.
Copyright Year	2014
Abstract	The management of metastatic pancreatic adenocarcinoma is a challenge for medical oncologists because of both the aggressive nature of the disease and the relative paucity of effective systemic treatments with activity against this type of tumor. In the effort to discover new agents and combinations that may augment the therapeutic arsenal available for the management of this cancer, early phase clinical trials have been performed using ixabepilone, an epothilone B analog, with promising results. Targeting the microtubule system with certain taxanes in the management of pancreatic adenocarcinoma has been validated; ixabepilone also targets the microtubule system, interfering with it in an alternate manner from the taxane mechanism. Ixabepilone has demonstrated activity in cancers that have become taxane-resistant as well as those that never had any demonstrable taxane susceptibility. The available data for the use of ixabepilone in the management of pancreatic adenocarcinoma are limited but promising. Single-arm studies have demonstrated both clinical efficacy and tolerable toxicity for the use of ixabepilone as monotherapy. The trial data available for ixabepilone used as a part of combination therapy are similar: it has been paired with chemotherapy (carboplatin, irinotecan) and biologic therapy (dasatinib, sunitinib) at the Phase I level to treat solid tumors in general, again with tolerable side effects and a suggestion of benefit. A single Phase II study has evaluated combination therapy with ixabepilone in the management of patients with pancreatic cancer, pairing it with cetuximab with clinical benefit. Although these trials are promising with regard to addition of ixabepilone to the slim armamentarium for management of pancreatic cancer, further work is still to be done. Importantly, this work bears the burden of not only validating the clinical benefit of ixabepilone, but also of determining whether this benefit is enhanced in any way by combination therapy, and where ixabepilone fits in the sequence of management for patients with metastatic pancreatic cancer.
Related Links	http://dx.doi.org/10.2147/dddt.s52964
Ending Page	930
Page Count	8
Starting Page	923
File Format	PDF
ISSN	11778881
e-ISSN	11778881
Journal	Drug Design, Development and Therapy
Volume Number	8
Language	English
Publisher	Dove Medical Press
Publisher Date	2014-07-01
Access Restriction	Open
Rights Holder	Dove Medical Press
Subject Keyword	Pharmacology Drug Discovery Pharmaceutical Science Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Drug Discovery Pharmacology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Profile of alisporivir and its potential in the treatment of hepatitis C

Profile of certolizumab and its potential in the treatment of psoriatic arthritis

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus [Corrigendum]

Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections

Profile and potential of ixabepilone in the treatment of pancreatic cancer

Similar Documents

Profile of alisporivir and its potential in the treatment of hepatitis C

Profile of certolizumab and its potential in the treatment of psoriatic arthritis

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus [Corrigendum]

Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections

Profile and potential of ixabepilone in the treatment of pancreatic cancer